阿托伐他汀钙治疗扩张型心肌病合并蛋白尿的研究

The research of atorvastatin calcium therapy on dilated cardiomyopathy with albuminuria

目的观察使用阿托伐他汀钙治疗扩张型心肌病患者合并蛋白尿的疗效、安全性。方法将60例扩张型心肌病合并蛋白尿患者随机分为观察组和对照组各30例,2组均常规给予洋地黄强心,血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂、β受体阻滞剂、醛固酮类等药物逆转心室重构等标准治疗,观察组在此治疗基础上加用阿托伐他汀钙,观察2组疗效及安全性,检测治疗前后尿蛋白减少情况。结果观察组治疗后3个月、6个月、12个月24h尿蛋白减少有效率(20.00%、56.67%、76.67%)与对照组同期(3.33%、20.00%、20.00%)比较,差异有统计学意义(P<0.05),且无明显不良反应。结论阿托伐他汀钙可以明显降低扩张型心肌病患者合并出现的蛋白尿。

Objective To research the clinical effects and safety of atorvastatin calcium therapy on dilated cardiomyopathy with albuminuria.Methods Sixty patients with dilated cardiomyopathy with albuminuria were randomly divided into observation group and control group,and each group was 30 patients.The control group was used to take digitalis,ACEI or ARB,β-receptor blocking pharmacon and aldosterone in order to reverse ventricular remodeling.On the basis of the control group,atorvastatin calcium was added to the treatment of the observation group.The clinical effects and safety between two groups were observed and compared.Before and after treatment the changes of urine protein were detected.Results The effective rate of the observation group was better than that of the control group（P〈0.05）.After 3,6 and 12 months treatment,the albuminuria decreased rate of observation group was 20.00%,56.67% and 76.67% respectively,while the rate of the control group was 3.33%、20.00% and 20.00%,there were significant differences（P〈0.05）,and noobvious side effects were observed.Conclusions The atorvastatin calcium therapy can obviously reduce the albuminuria of dilated cardiomyopathy patient.